Learning female head anatomy is an essential starting point for beginners who want to draw portraits with confidence and ...

This video reacts to a fast Minecraft tutorial that shows how to build a simple automatic door using redstone. The build uses ...

SRIKAKULAM: In a modest government school in Pathapatnam, students walk into a biology lab that feels more like an art ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Hedge funds betting on drugs stocks have made bumper profits this year, as a recent wave of deals by big ...

The Trump administration’s ambition to unleash biomedical innovation and sharpen America’s edge against China is colliding with a far messier reality inside the Food and Drug Administration. Investors ...

If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...

The European Union’s upcoming Biotech Act is hotly anticipated in the world of food. The Act could be integral to food innovation, streamlining regulation in areas such as precision fermentation. The ...

Reader, beware: You’re entering haunted grounds. Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're embracing the spooky spirit of ...

In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...

Biotech ETFs offer diversified exposure to multiple biotech stocks, reducing individual investment risk. Top biotech ETFs, like iShares and SPDR S&P, have large assets and low expense ratios.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...